Literature DB >> 23420235

Comparative effectiveness of treatments for open-angle glaucoma: a systematic review for the U.S. Preventive Services Task Force.

Michael V Boland1, Ann-Margret Ervin, David S Friedman, Henry D Jampel, Barbara S Hawkins, Daniela Vollenweider, Yohalakshmi Chelladurai, Darcy Ward, Catalina Suarez-Cuervo, Karen A Robinson.   

Abstract

BACKGROUND: Glaucoma is an acquired degeneration of the optic nerve and a leading cause of blindness worldwide. Medical and surgical treatments that decrease intraocular pressure may prevent visual impairment and blindness.
PURPOSE: To compare the effectiveness of medical, laser, and surgical treatments in adults with open-angle glaucoma with regard to decreasing intraocular pressure and preventing optic nerve damage, vision loss, and visual impairment. DATA SOURCES: MEDLINE, CENTRAL, and an existing database for systematic reviews (through 2 March 2011); MEDLINE, EMBASE, LILACS, and CENTRAL for primary studies (through 30 July 2012). STUDY SELECTION: English-language systematic reviews; randomized, controlled trials; and quasi-randomized, controlled trials for most outcomes and observational studies for quality of life and harms. DATA EXTRACTION: Two investigators abstracted or checked information about study design, participants, and outcomes and assessed risk of bias and strength of evidence. DATA SYNTHESIS: High-level evidence suggests that medical, laser, and surgical treatments decrease intraocular pressure and that medical treatment and trabeculectomy reduce the risk for optic nerve damage and visual field loss compared with no treatment. The direct effect of treatments on visual impairment and the comparative efficacy of different treatments are not clear. Harms of medical treatment are primarily local (ocular redness, irritation); surgical treatment carries a small risk for more serious complications. LIMITATION: Heterogeneous outcome definitions and measurements among the included studies; exclusion of many treatment studies that did not stratify results by glaucoma type.
CONCLUSION: Medical and surgical treatments for open-angle glaucoma lower intraocular pressure and reduce the risk for optic nerve damage over the short to medium term. Which treatments best prevent visual disability and improve patient-reported outcomes is unclear.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23420235     DOI: 10.7326/0003-4819-158-4-201302190-00008

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  85 in total

1.  Extraction (DSX) from Erigeron breviscapus modulates outward potassium currents in rat retinal ganglion cells.

Authors:  Shuo Yin; Zhong-Feng Wang; Jun-Guo Duan; Lu Ji; Xue-Jing Lu
Journal:  Int J Ophthalmol       Date:  2015-12-18       Impact factor: 1.779

2.  Rapid network meta-analysis using data from Food and Drug Administration approval packages is feasible but with limitations.

Authors:  Lin Wang; Benjamin Rouse; Arielle Marks-Anglin; Rui Duan; Qiyuan Shi; Kevin Quach; Yong Chen; Christopher Cameron; Christopher H Schmid; Tianjing Li
Journal:  J Clin Epidemiol       Date:  2019-06-18       Impact factor: 6.437

3.  Angiopoietin receptor TEK mutations underlie primary congenital glaucoma with variable expressivity.

Authors:  Tomokazu Souma; Stuart W Tompson; Benjamin R Thomson; Owen M Siggs; Krishnakumar Kizhatil; Shinji Yamaguchi; Liang Feng; Vachiranee Limviphuvadh; Kristina N Whisenhunt; Sebastian Maurer-Stroh; Tammy L Yanovitch; Luba Kalaydjieva; Dimitar N Azmanov; Simone Finzi; Lucia Mauri; Shahrbanou Javadiyan; Emmanuelle Souzeau; Tiger Zhou; Alex W Hewitt; Bethany Kloss; Kathryn P Burdon; David A Mackey; Keri F Allen; Jonathan B Ruddle; Sing-Hui Lim; Steve Rozen; Khanh-Nhat Tran-Viet; Xiaorong Liu; Simon John; Janey L Wiggs; Francesca Pasutto; Jamie E Craig; Jing Jin; Susan E Quaggin; Terri L Young
Journal:  J Clin Invest       Date:  2016-06-06       Impact factor: 14.808

4.  Intranasal Corticosteroids Do Not Lead to Ocular Changes: A Systematic Review and Meta-analysis.

Authors:  Carla V Valenzuela; James C Liu; Peter M Vila; Laura Simon; Michelle Doering; Judith E C Lieu
Journal:  Laryngoscope       Date:  2018-09-19       Impact factor: 3.325

5.  Palmitic acid triggers cell apoptosis in RGC-5 retinal ganglion cells through the Akt/FoxO1 signaling pathway.

Authors:  Panshi Yan; Shu Tang; Haifeng Zhang; Yuanyuan Guo; Zhiwen Zeng; Qiang Wen
Journal:  Metab Brain Dis       Date:  2016-12-07       Impact factor: 3.584

Review 6.  [Possibilities and limitations of eye drops for glaucoma therapy].

Authors:  I M Lanzl; M Poimenidou; G L Spaeth
Journal:  Ophthalmologe       Date:  2016-10       Impact factor: 1.059

7.  Efficacy of selective laser trabeculoplasty following incisional glaucoma surgery.

Authors:  Robert Allan Sharpe; Leah L Kammerdiener; David B Williams; Sudeep K Das; Matthew J Nutaitis
Journal:  Int J Ophthalmol       Date:  2018-01-18       Impact factor: 1.779

8.  Managing high risk glaucoma with the Ahmed valve implant: 20 years of experience.

Authors:  Tryfon Rotsos; Anastasia Tsioga; Konstantinos Andreanos; Andreas Diagourtas; Petros Petrou; Ilias Georgalas; Dimitrios Papaconstantinou
Journal:  Int J Ophthalmol       Date:  2018-02-18       Impact factor: 1.779

9.  Effect of Cromakalim Prodrug 1 (CKLP1) on Aqueous Humor Dynamics and Feasibility of Combination Therapy With Existing Ocular Hypotensive Agents.

Authors:  Uttio Roy Chowdhury; Tommy A Rinkoski; Cindy K Bahler; J Cameron Millar; Jacques A Bertrand; Bradley H Holman; Joseph M Sherwood; Darryl R Overby; Kristen L Stoltz; Peter I Dosa; Michael P Fautsch
Journal:  Invest Ophthalmol Vis Sci       Date:  2017-11-01       Impact factor: 4.799

10.  Sub-region-Specific Optic Nerve Head Glial Activation in Glaucoma.

Authors:  Kazuya Oikawa; James N Ver Hoeve; Leandro B C Teixeira; Kevin C Snyder; Julie A Kiland; N Matthew Ellinwood; Gillian J McLellan
Journal:  Mol Neurobiol       Date:  2020-04-07       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.